atc sales, page-3

Buy! Sell! More Wheeling, Dealing from Bristol-Myers CEO
* October 22, 2009, 1:45 PM ET

If you’re running a little biotech shop with tons of promise but not much capital, here’s a tip: Jim Cornelius has a billion dollars burning a hole in his pocket.

Cornelius is the CEO of Bristol-Myers Squibb; on the company’s earnings call today he said that even after Bristol’s recent $2.1 billion Medarex deal, the company’s net cash position is $1.3 billion. And Bristol will “continue to aggressively pursue acquisitions, licensing deals and other partnerships,” he said.

Bristol may get even more cash — another $1.7 billion or so — when Mead Johnson, a former Bristol subsidiary that had an IPO earlier this year, closes on some debt refinancing, Cornelius said.



>>By the way their HIV products 3rd qtr sales are just out

pi reyataz 360M for 1.4B
nnrti sustiva 300M for 1.2B

seem to be missing an nrti dont they